SCR 87 is a California concurrent resolution that designates June 10, 2025 as Focal Segmental Glomerulosclerosis (FSGS) Awareness Day. The measure collects medical and epidemiological findings—about diagnostic delay, progression to kidney failure, racial disparities tied to APOL1 variants, and emerging clinical trials—and uses them to justify the observance.
The resolution is purely symbolic: it does not appropriate funds, change regulatory obligations, or create enforceable rights. Its practical value lies in signaling priorities to state agencies, clinicians, researchers, patient groups, and payers; it can be used as a public-facing tool to coordinate outreach, education, and advocacy around diagnosis, access to nephrology care, and clinical research participation.
At a Glance
What It Does
The bill formally designates June 10, 2025 as Focal Segmental Glomerulosclerosis Awareness Day in California and directs the Secretary of the Senate to transmit copies of the resolution. It compiles factual findings about FSGS—disease progression, diagnosis delays, racial risk factors, cost estimates, and ongoing clinical trials—but imposes no regulatory or funding requirements.
Who It Affects
Directly affected parties include patients and families with FSGS, kidney disease advocacy groups, nephrology clinics and researchers, and state legislative staff responsible for distributing the resolution. Indirectly, insurers, health systems, and public health communicators may use the designation for outreach or programmatic justification.
Why It Matters
Even though ceremonial, the resolution creates a dated, repeatable occasion for awareness campaigns that can amplify fundraising, patient recruitment for trials, and pressure for improved specialty access. It also codifies specific claims—about costs, racial disparities, and trial activity—that stakeholders will reference in future advocacy or policy proposals.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SCR 87 is a short, fact-heavy concurrent resolution that ends by declaring a single awareness day and asking the Secretary of the Senate to circulate the text. The bulk of the document is a set of 'whereas' findings: national and international data points on chronic kidney disease, FSGS progression to kidney failure, diagnostic delays for rare diseases, racial disparities linked to APOL1 gene variants, and the economic burden on insurers.
The text also highlights ongoing clinical work and efforts to validate proteinuria as an intermediate marker for treatment effect.
Legally, the measure does not create programmatic obligations. Concurrent resolutions in California offer a public posture but do not alter statutes, appropriate money, or compel state agencies to act.
Where such resolutions have effect is operational: state and local public health offices, professional associations, and advocacy groups often use designated days to mount campaigns, issue guidance, or convene stakeholders. SCR 87 supplies a succinct, legislatively-endorsed rationale that those actors can cite when seeking partnerships, media coverage, or private funding.Practically, the resolution may modestly change behavior.
Awareness days can increase referrals to specialists in the short term, boost patient enrollment in registries and trials, and attract philanthropic interest. But the bill itself does not address the underlying capacity problems it notes—such as nephrology workforce shortages or insurer coverage rules—so any downstream change depends on follow-on actions by agencies, payers, or private funders.
The resolution also foregrounds genetic risk (APOL1) and cost figures that advocates can use in legislative or budgetary requests going forward.Finally, SCR 87 signals priorities to researchers and industry by explicitly noting that clinical trials and validation of surrogate endpoints are underway. That acknowledgment may smooth coordination between California-based investigators, trial sponsors, and patient groups when they design outreach tied to the awareness day, but it does not alter trial regulation or approval pathways.
The Five Things You Need to Know
The resolution designates June 10, 2025 as Focal Segmental Glomerulosclerosis Awareness Day in California.
SCR 87 is ceremonial: it contains findings and a designation but does not authorize spending, change law, or create enforceable rights.
The bill cites clinical statistics including that roughly 50% of patients with FSGS require dialysis or a kidney transplant within 5–10 years of diagnosis.
The text highlights racial disparities—citing a 4–5x higher occurrence among African Americans—and calls out APOL1 high-risk variants as a major contributor to that burden.
The resolution directs the Secretary of the Senate to transmit copies of the resolution to the author for distribution.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Findings on prevalence, progression, disparities, costs, and research
The 'whereas' preamble aggregates epidemiology (one in seven adults with chronic kidney disease), disease-specific claims (FSGS progression and transplant recurrence rates), diagnostic delay, workforce shortages in nephrology, racial disparities tied to APOL1, and a 2019 cost estimate of about $2 billion annually to insurers. These findings do two things practically: they provide a compact evidence base advocates can cite, and they frame FSGS as both a clinical and health‑equity issue—language designed to broaden the political constituency for any future policy action.
Creates Focal Segmental Glomerulosclerosis Awareness Day
This operative clause formally designates June 10, 2025 as FSGS Awareness Day in California. Because it is a concurrent resolution, the designation is symbolic and does not require state agencies to adopt programs or allocate funds. However, the date gives public-health offices, clinicians, and advocacy groups a legislatively-sanctioned hook for outreach, education, fundraising, and event coordination.
Administrative distribution instruction
The resolution instructs the Secretary of the Senate to transmit copies to the author for distribution. That administrative step is minimal but ensures stakeholders receive an official, stamped document they can include in outreach materials. The instruction does not trigger further administrative action or reporting obligations.
No fiscal committee referral or appropriation
The legislative counsel's digest and the bill metadata note 'Fiscal Committee: NO,' and the measure contains no appropriation language. Practically, this confirms the Legislature considered the resolution nonfiscal and nonbinding. Any financial implications—such as funding for outreach or increased clinical demand—would need separate statutory or budgetary action.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients with FSGS and their families — The designation creates a public outlet for awareness, peer support events, and may increase referrals and trial enrollment when coordinated by clinicians and advocacy groups.
- Patient advocacy organizations (e.g., NephCure) — They gain a legislatively-backed platform to raise funds, publicize screening materials, and push for further policy or budgetary changes.
- Researchers and clinical trial sponsors — The awareness day can aid recruitment, publicize registry enrollment, and legitimize efforts to validate proteinuria and other surrogate markers.
- Clinics and nephrologists — Awareness campaigns can produce short-term increases in referral volume and opportunities for community outreach and continuing medical education.
- Public health communicators — State and local health offices acquire a dated event they can use to coordinate messaging and partnerships with community groups.
Who Bears the Cost
- Legislative administrative staff — Minimal time and copying/distribution costs tied to transmitting and posting the resolution.
- State and local public health offices that choose to act — If agencies mount campaigns tied to the day, they will need to absorb outreach, staff time, or materials costs unless separately funded.
- Nephrology clinics and hospitals — A potential short-term rise in referrals could strain specialty capacity, prompting triage or added scheduling burdens.
- Insurers and payers — If awareness activities lead to more diagnostic testing or specialty consultations, payers could see increased short‑term utilization absent parallel changes in coverage policy.
- Researchers and trial sponsors — While benefiting from recruitment opportunities, they may face heightened administrative demands to scale enrollment and ensure equitable outreach.
Key Issues
The Core Tension
The central dilemma is symbolic recognition versus substantive change: SCR 87 elevates FSGS visibility and legitimizes advocacy, but it does not address the resource, coverage, workforce, or privacy issues that cause diagnostic delay, inequitable outcomes, and treatment access—so the act of naming a day can both help organize action and, unintentionally, create expectations the Legislature has not funded or mandated.
SCR 87 is emphatically symbolic. Its strength is rhetorical: it packages a set of clinical and equity claims into a legislative finding that stakeholders can cite.
That rhetorical power can be useful in advocacy and outreach, but the resolution leaves four important gaps. First, it does not fund workforce expansion or specialty access, so declared awareness may increase demand without increasing supply.
Second, the bill highlights APOL1 genetic risk without addressing genetic counseling, data privacy, or potential insurance implications for people identified as high-risk. Third, the resolution relies on selected statistics (including UK RaDaR registry findings and a 2019 cost estimate) that may not map precisely to California’s population or current cost landscape, which could complicate argumentation that seeks state budgetary support.
Fourth, by naming an awareness day tied to clinical trial activity and surrogate markers, the resolution risks creating public expectations about imminent treatments even though approval and access remain uncertain.
Implementation questions are practical rather than legal: which state or local agencies, if any, will run campaigns; whether outreach prioritizes historically impacted communities; how messages will balance hope about research with realistic timelines for therapies; and whether increased testing driven by awareness will be covered by insurers. Those unresolved items determine whether the designation translates into measurable clinical or equity outcomes or remains a one-day observance with limited downstream effect.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.